The global antibody-mediated rejection prevention market is expected to be valued at US$ 89 million in 2023 and is projected to rise at a CAGR of 16% from 2023 to 2033. A valuation of US$ 528.31 million has been estimated by the end of the said decade. During the last decade, the complement system has gained prominence as a significant component of the AMR market. The primary goal of using complement inhibitors is to prevent DSA-induced allograft damage. As a result, it is expected to spur market growth.
Emerging technologies, such as genomic research and donor-specific antibody detection and definition assays, have provided significant insights into the pathophysiology and prognosis of severe antibody-mediated rejection. As a result, this aspect contributed heavily to the antibody-mediated rejection prevention industry. Antibody-mediated rejection prevention is predicted to exhibit a substantial increase due to increasing pervasiveness and the anticipated unveiling of therapeutic strategies such as Clazakizumab, Imlifidase, VIB4920, Inebilizumab-cdon, Daratumumab, and others projected timeframe. The United States had the maximum AMR occurrence population, with around 3,266 cases in 2020.
According to Penn Medicine News, the shortage of kidneys remains a public health crisis in the United States. Every year, approximately 20,000 transplants are performed, and over 90,000 people are on the waiting list for kidney transplants. Furthermore, 5,000 people die while waiting for a transplant. As a result, rising late kidney transplant failure is expected to drive industry growth over the forecast period.
The rising incidence of chronic illnesses such as cancer, and heart disease, among others, is growing significantly for biologics, which is expected to drive the monoclonal antibodies segment. Correspondingly, expanding implementations of mAb treatments for therapeutic targets, as well as increased awareness of such treatment options among patients and doctors are predicted to contribute substantially to segment growth. On the other hand, Robust advancement and research against a variety of diseases, including multiple sclerosis, rheumatoid arthritis, Crohn's disorder, and many others, has led to the creation of new therapeutics, which are expected to aid in the Immunomodulators segment's expansion. Over the projected timeframe, the immunomodulators segment is predicted to expand at a CAGR of 6.3%.
North America is expected to dominate the market. This region's prominence is credited to the rising prevalence of illnesses among the US inhabitants. Another significant contribution to the region's growth is the existence of major players, combined with the introduction of innovative products. Europe ranks second in the market due to its investments in science and technology for the creation of efficient drugs. This, along with increased immunosuppressant sales revenue, is expected to propel the market growth during the forecast period. Furthermore, Asia Pacific is expected to experience the fastest CAGR due to the expanding number of clinical trial experiments pertaining to several drugs and the region's expanding geriatric population.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 89 million |
| Anticipated Forecast Value (2033) | US$ 528.31 million |
| Projected Growth Rate (2023 to 2033) | 16% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The COVID-19 pandemic hampered the production, dispersion, and manufacturing of pharmaceuticals worldwide. Furthermore, owing to social distancing, footfall in clinics and medical institutions has dropped by more than 70% throughout this pandemic, resulting in a reduction in the volume of surgical operations, clinical trials, activities for research and development, and other pursuits, all of which have hampered market growth in the historical period.
However, when the industries got back to their normal functioning some companies considerably enhanced their logistics operations, augmented their R&D capabilities, and are involved more in production management and quality assurance. According to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 14%.
An expanding geriatric population base to propel market expansion
The population with end-stage kidney impairment is getting older. Nearly half of all new patient populations are over the age of 65, and one-third are over the age of 70. As a result, late kidney transplant failure is prevalent in the elderly population, which is predicted to propel the antibody-mediated rejection prevention market throughout the forecast period.
According to a Pew Research Center report, the aged population in the United States will increase to 81 million by 2050, up from 37 million in 2005. As a consequence, this factor is anticipated to contribute to industry development.
A robust drug pipeline to aid in providing more development opportunities
Year after year, research and advancement with the goal of providing advanced patient care accelerates. Experimental studies with new or existing therapeutic agents are leading to combination treatment. It has resulted in an increase in pipeline aspirants for a variety of condition prevention strategies, including antibody-mediated rejection.
Plegridy and Daclizumab by Biogen, Ocrelizumab by Roche, and Receptors' RPC-1063 and Nerventra by Teva Pharmaceuticals, for example, are expected to be available on the market during the projected timeline. Such immunomodulators are expected to garner a significant market share in the coming years, resulting in industry growth.
Principal Consultant
Difficulties in constructing clinical trials to restrict market growth
There are obstacles to the expansion of the antibody-mediated rejection prevention market, such as difficulties in constructing clinical trials, a significant clinical burden, and the requirement for evidence-based treatment protocols.
Therapeutic approaches and Development of algorithms to detect AMR drive market growth
Few therapeutic interventions have received FDA approval in the United States. The first is belatacept, which was recently approved for the treatment of severe rejection in the United States. Belatacept impeded DSA in phase 3 trials, while there was more intense cellular refusal, renal function upgraded.
Besides that, DeKAF is an NIH-funded experimental research of late allograft failure that is being carried out at five transplant centers in the United States and two in Canada. DeKAF Genomics is a peripheral study of DeKAF that is connected to Medicare claims data for patients in the United States. As a result, this factor is expected to propel market expansion.
Furthermore, the region's dominance is due to the rising prevalence of diseases among the US population. Another significant contributing factor to the region's expansion is the existence of key players, combined with the emergence of new products.
Increasing Medical Expenditure is Spurring Demand for Antibody-mediated Rejection Prevention
Europe ranks second in the market due to its investments in scientific and technological research for the creation of high-quality drugs. Furthermore, according to a National Institute for Health and Care Excellence article, there were 4,647 individuals on the UK kidney waitlist in March 2019, and 3,280 adult kidney-only transplants in the UK in 2018/19 (with 71% coming from deceased donors). As a result, this factor is anticipated to contribute to market growth.
Collaboration efforts by the largest pharmaceutical and clinical-stage development firms, on the other side, will provide fresh avenues for monoclonal antibody expansion, which is anticipated to contribute to market expansion.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Monoclonal Antibodies to Lead the Treatment Type of Antibody-mediated Rejection Prevention
The global monoclonal antibodies segment was worth US$ 186 million in 2021, and it is expected to expand at a compound annual growth rate (CAGR) of 11% between 2023 and 2033.
Because mAbs are a potential solution for COVID-19 remediation owing to their safety and efficiency, the U.S. FDA has granted several antibody emergency use authorizations (EUA). As a result, these factors are anticipated to propel the monoclonal antibodies segment during the forecast period.
Hospital Segment is Estimated to Hold the Largest Share
The hospital segment is predicted to maintain a dominant position in the market throughout the forthcoming years due to a rise in hospitalization rates and hospital healthcare services. Furthermore, between 2023 and 2033, the same segment is expected to experience the fastest CAGR.
Key players in the Antibody-mediated Rejection Prevention market are CSL Behring, Hansa Biopharma, Sanofi, Talaris Therapeutics, Horizon Therapeutics, Novartis AG, Biogen, Teva Pharmaceutical Industries Ltd., Eli Lilly, and Company, Bristol-Myers & Squibb Company. Some of the recent developments are below:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 89 million |
| Market Value in 2033 | US$ 528.31 million |
| Growth Rate | CAGR of 16% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2023-2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The global adoption of antibody-mediated rejection prevention services could register 16% CAGR through 2033.
The global sales on an average exhibited a y-o-y increment of 14% from 2018 to 2022.
The hospital segment is projected to maintain its dominance by growing at a higher CAGR through 2033.
The monoclonal antibodies segment is forecasted to expand at 11% CAGR until 2033.
Therapeutic interventions like belatacept are likely to advance the overall demand in the country.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Monoclonal Antibodies
5.3.2. Cysteine Protease Inhibitors
5.3.3. Immunomodulators
5.3.4. Plasmapheresis
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End User
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Treatment
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By End User
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By End User
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By End User
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By End User
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By End User
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By End User
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By End User
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By End User
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By End User
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By End User
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By End User
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By End User
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By End User
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By End User
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By End User
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By End User
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. CSL Behring
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Hansa Biopharma
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Sanofi
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Talaris Therapeutics
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Horizon Therapeutics
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Novartis AG
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Biogen
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Teva Pharmaceutical Industries Ltd.
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Eli Lilly and Company
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Bristol-Myers & Squibb Company
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Antibody-mediated Rejection Prevention Market
